Skip to main content

Table 2 Classification of adjuvant chemotherapy regimens

From: Progress in adjuvant chemotherapy for breast cancer: an overview

Generation* Benefit Regimens with substantial evidence base
First 35 % reduction in breast cancer mortality compared with no adjuvant chemotherapy CMFx6, ACx4, FEC50x6
Second 20 % reduction in breast cancer mortality compared with first generation regimen FEC100x6, CAFx6, FACx6
ACx4-Tx4 (q3wks)
DCx4, Ex4-CMFx4
Third 20 % reduction in breast cancer mortality compared with second generation regimen FECx4-Dx3, FECx4-weekly Tx8
Concurrent DAC
Dose-dense ACx4-Tx4
ACx4-weekly paclitaxel
ACx4-docetaxel (q 3 weeks)
  1. *Adopted from Adjuvant online with modifications [50, 51]
  2. CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m2), cyclophosphamide; FEC100, 5-flourouracil, epirubicin (100 mg/m2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide, doxorubicin, 5-flourouracil; FAC, 5-flouroracil, doxorubicin, cyclophosphamide; DAC, Docetaxel, doxorubicin, cyclophosphamide; T, paclitaxel; D, Docetaxel; E, Epirubicin